A Study of Olaratumab (LY3012207) Plus Pembrolizumab in Participants With Advanced or Metastatic Soft Tissue Sarcoma

I5B-MC-JGDQ -

The purpose of this study is to evaluate the safety of olaratumab plus pembrolizumab in participants with previously treated advanced or metastatic soft tissue sarcoma.

Trial Summary

Age Range
≥18 years
Conditions the trial is for
Soft Tissue Sarcoma
What the trial is testing?
Olaratumab, Pembrolizumab
Could I receive a Placebo?
No
Enrollment Goal
38
Trial Dates
Jul 3, 2017 - Feb 21, 2023
How long will I be in the trial?
The duration of your participation depends on how well your disease responds to the study treatment.
Trial Phase
I

Key Requirements

Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.

Participants Must:

  • Participant must have a diagnosis of advanced unresectable or metastatic soft tissue sarcoma confirmed by histology

  • Participant must be able to provide tumor tissue obtained within 6 months of enrolling in the study (if no such tissue is available, must be willing to provide a core or excisional biopsy)

  • Participant must have an anticipated life expectancy of 3 months or more

Participants Must Not:

  • Participant must not have active autoimmune disease or any other syndrome that require systemic steroids or autoimmune agents in the past 2 years

  • Participant must not have received a live-virus vaccine within 30 days of planned treatment

  • Participant must not have inflammatory bowel disease for which immunosuppressive agents were used in the last 2 years

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.

Clinical Trial Resources